Capital International discloses 7.7% of Royalty Pharma

Rhea-AI Filing Summary

Capital International Investors, a division of Capital Research and Management Company and affiliated investment management entities, reports beneficial ownership of 32,745,526 shares of Royalty Pharma PLC common stock, representing 7.7% of the 427,247,489 shares believed outstanding as of the event date.

The firm has sole voting power over 32,581,425 shares and sole dispositive power over 32,745,526 shares, with no shared voting or dispositive power. The securities are certified as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Royalty Pharma.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Royalty Pharma (RPRX) does Capital International Investors report owning?

Capital International Investors reports beneficial ownership of 7.7% of Royalty Pharma PLC’s common stock. This percentage is based on 32,745,526 shares out of 427,247,489 shares believed to be outstanding as referenced in the Schedule 13G/A ownership section.

How many Royalty Pharma (RPRX) shares does Capital International Investors beneficially own?

Capital International Investors is deemed the beneficial owner of 32,745,526 Royalty Pharma PLC common shares. The filing also notes sole voting power over 32,581,425 shares and sole dispositive power over 32,745,526 shares, with no shared voting or dispositive authority reported.

Is Capital International Investors a passive investor in Royalty Pharma (RPRX)?

The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Royalty Pharma. It expressly disclaims acquisition in connection with any control-related transaction, except activities tied to a specific nomination rule.

What key dates are disclosed in Capital International Investors’ Royalty Pharma (RPRX) Schedule 13G/A?

The Schedule 13G/A lists 12/31/2025 as the date of the event requiring the statement. The certification is signed and dated 02/12/2026 by an authorized representative, establishing the timing of the reported ownership information and its subsequent confirmation.

Who signed the Schedule 13G/A for Capital International Investors regarding Royalty Pharma (RPRX)?

The statement is signed by Jae Won Chung, identified as Vice President and Senior Counsel II of Capital Research and Management Company. The signature appears under a certification that the information provided about the ownership of Royalty Pharma securities is true, complete, and correct.

What is Capital International Investors’ voting and dispositive power over Royalty Pharma (RPRX) shares?

Capital International Investors reports sole voting power over 32,581,425 Royalty Pharma shares and sole dispositive power over 32,745,526 shares. The filing indicates no shared voting power and no shared dispositive power with respect to the issuer’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:29 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Royalty Pharma PLC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

G7709Q104

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G7709Q104

1

Names of Reporting Persons

Capital International Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 32,581,425.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 32,745,526.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

32,745,526.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.7 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Royalty Pharma PLC
(b)	Address of issuer's principal executive offices: 110 EAST 59TH STREET, NEW YORK, NY 10022
Item 2.
(a)	Name of person filing: Capital International Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: G7709Q104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 32,745,526 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 32,745,526 shares or 7.7% of the 427,247,489 shares believed to be outstanding.
(b)	Percent of class: 7.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 32,581,425
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 32,745,526
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital International Investors

Signature:	Jae Won Chung
Name/Title:	Vice President and Senior Counsel II, Capital Research and Management Company
Date:	02/12/2026